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Background. Non-(1-84) parathyroid hormone (PTH) frag-
ments are large circulating carboxyl-terminal (C) fragments
with a partially preserved amino-terminal (N) structure. hPTH
(7-84), a synthetic surrogate, has been demonstrated to exert
biologic effects in vivo and in vitro which are opposite to those
of hPTH (1-34) on the PTH/PTHrP type I receptor through a
C-PTH receptor. We wanted to determine the N structure of
non-(1-84) PTH fragments.
Methods. Parathyroid cells isolated from glands obtained at
surgery from three patients with primary hyperparathyroidism
and three patients with secondary hyperparathyroidism were
incubated with 35S-methionine to internally label their secre-
tion products. Incubations were performed for 8 hours at the
patient-ionized calcium concentration and in the presence of
various protease inhibitors. The supernatant was fractionated
by high-performance liquid chromatography (HPLC) and frac-
tions were analyzed with PTH assays having (1 to 4) and (12
to 23) epitopes, respectively. The serum of each patient was
similarly analyzed. Peaks of immunoreactivity identified were
submitted to sequence analysis to recover the 35S-methionine
residues in positions 8 and 18.
Results. Three regions of interest were identified with PTH
assays. They corresponded to non-(1-84) PTH fragments (fur-
ther divided in regions 3 and 4), a peak of N-PTH migrating in
front of hPTH (1-84) (region 2) and a peak of immunoreactivity
corresponding to the elution position of hPTH (1-84) (region 1).
The last corresponded to a single sequence starting at position
1. Region 2 gave similar results in all cases (a major signal start-
ing at position 1) but also sometimes minor sequences starting
at position 4 or 7. Regions 3 and 4 always identified a major
sequence starting at positions 7 and minor sequences starting
at positions 8, 10, and 15. Surprisingly, a major signal starting at
position 1 was also present in region 3. The HPLC profile ob-
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tained from a given patient’s parathyroid cells was qualitatively
similar to the one obtained with his/her serum in each case.
Conclusion. These results indicate that non-(1-84) PTH frag-
ments are composed of a family of fragments which may be
generated by specific or progressive cleavage at the N region.
The longest fragment starts at position 4 and the shortest at
position 15. A peptide starting at position 7 appears as the ma-
jor component of non-(1-84) PTH fragments. The generation
process is similar to the one described for smaller C-PTH frag-
ments a number of years ago, suggesting a similar production
mechanism and source for all C-PTH fragments.
Non-(1-84) parathyroid hormone (PTH) fragments or
amino-terminal (N) truncated PTH fragments are large
circulating carboxyl-terminal (C) fragments of PTH with
a partially preserved N structure. They differ from other
circulating C-PTH fragments (which make up the ma-
jority of PTH in circulation) by their capacity to react
in intact (i) or (13-34) PTH assays [1–3]. Non-(1-84) C-
PTH fragments were initially described during a study of
parathyroid function in normal individuals [1]. When cir-
culating PTH molecular forms were fractionated by high-
performance liquid chromatography (HPLC) at various
calcium concentrations, a slightly less hydrophobic peak
of immunoreactivity was identified in front of hPTH (1-
84) and named non-(1-84) PTH. This peak represented
about 20% of iPTH in a normal individual under normo-
calcemic condition but up to 50% in patients with ter-
minal renal failure [1–3]. Like other C-PTH fragments
[4], non-(1-84) PTH fragments are cleared by the kid-
ney and thus accumulate in renal failure patients propor-
tionally to the degree of renal failure [5]. They are also
secreted by the parathyroid glands [6] and generated dur-
ing the peripheral metabolism of hPTH (1-84) [6]. The
exact N-terminal structure of non-(1-84) PTH fragments
is unknown but a recent immunologic study based on
the use of antibodies with proximal or distal epitopes in
the region (13-34) of the PTH structure suggests that all
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non-(1-84) PTH fragments start their N structure prior to
position 19 [7].
Our interest in non-(1-84) PTH fragments lies in the
fact that they could exert biologic effects different from
those of hPTH (1-84). hPTH (7-84), a commercially avail-
able surrogate for all non-(1-84) PTH fragments, was
initially used to demonstrate that such fragments re-
acted in iPTH assays [2, 3]. It has been also used to
demonstrate that this category of C-PTH fragments ex-
erts biologic effects different from those of hPTH (1-
84) via a C-PTH receptor [8–11]. hPTH (7-84) causes
hypocalcemia, hypophosphatemia, and antagonizes the
calcemic response to hPTH (1-34) and hPTH (1-84) in
parathyroidectomized rats [8, 9]. It is also an inhibitor
of bone resorption in vitro [11] and of bone turnover in
parathyroidectomized 5/6 nephrectomized rats [10]. It is
thus important to determine the N-terminal structure of
non-(1-84) PTH fragments to see if they could duplicate
the biologic effects observed with hPTH (7-84).
METHODS
Experimental subjects
Three patients with primary hyperparathyroidism and
three others with secondary hyperparathyroidism, who,
upon investigation, had a large amount of parathyroid
tissue, were recruited for this project. The study was ap-
proved by the Research Ethics Committee of our center,
and all participants signed an informed consent.
Experimental protocols
Blood was obtained from each subject prior to surgery
to measure indices of calcium metabolism and to perform
HPLC separation of circulating PTH molecular forms.
Parathyroid tissue taken at surgery was brought to pathol-
ogy where a portion was kept for pathologic analysis and
another was used for experimentation. Five hundred mil-
ligrams of tissue proved necessary for successful experi-
mentation with parathyroid cells.
Biochemical measurements
Ionized calcium (Ca++) was measured by a specific
electrode (Rapid Lab 348) (Bayer, Toronto, Ontario,
Canada), while total calcium (Cat), phosphorus (PO4),
creatinine, and alkaline phosphatase (AP) were quan-
tified by automated colorimetric methods. PTH was
measured in serum and in HPLC fractions by two
enzyme-linked immunosorbent assays (ELISAs) pro-
vided by Immutopics Inc. (San Clemente, CA, USA),
the Human Bioactive PTH ELISA and the Human PTH
ELISA. Both assays use a capture antibody purified by
affinity chromatography against hPTH (39-84). The Hu-
man Bioactive PTH ELISA has a (1-4) epitope [12].
The revealing antibody of the Human PTH ELISA was
purified by affinity chromatography against hPTH (13-
34). We also developed a carboxyl-terminal radioim-
munoassay (RIA) with a (79-84) immunoaffinity purified
antibody provided by Immutopics Inc. and 125I [tyr53]
hPTH(53-84) as tracer. The antibody was first purified
by affinity chromatography against hPTH (39-84) and
further purified by the same method against hPTH (79-
84). The behavior of each assay was studied using ap-
propriate hPTH standards. These included hPTH (1-84),
hPTH (7-84), [tyr34] hPTH (19-84), [tyr34] hPTH (24-84),
hPTH (39-84), hPTH (53-84), hPTH (64-84), and hPTH
(53-83). Saturation analysis of the revealing antibody of
the two PTH ELISAs was also performed with hPTH
(1-34), hPTH (13-34), and hPTH (18-48). All peptides
were purchased from Bachem (Torrance, CA, USA) ex-
cept for hPTH (53-83), [tyr34] hPTH (19-84), and [tyr34]
hPTH (24-84) which were generously provided by Dr.
H. Ju¨ppner of the Massachusetts General Hospital in
Boston.
Parathyroid cell incubation
Parathyroid tissue obtained at surgery was separated
from fat and connective tissue, and minced into small
pieces. These pieces were digested with collagenase type
I (Worthington, 239 U/mg) and DNase type I (Worthing-
ton, 3.08 U/mg) [13]. The first was used at a concen-
tration of 20 mg/200 mg of tissue while the second was
used at 500 lg/200 mg. Both were dissolved in Dulbecco’s
modified Eagle’s medium (DMEM)/F-12, 10% fetal calf
serum (FCS), 0.2% bovine serum albumin (BSA) at
10 mL/200 mg of tissue. Digestion proceeded for 60 min-
utes at 37◦C or overnight at 4◦C. The medium was then fil-
tered through a nylon filter (250 lmol/L) and centrifuged
at 3500 rpm at 4◦C over 10 minutes. After the supernatant
was discarded, the pellet was resuspended in digestion
medium lacking methionine and washed three times. The
cells were then incubated in 10 mL of the same medium
in a 25 cm3 flask at 37◦C for 4 hours. Ca++ concentra-
tion was adjusted to the original Ca++ concentration of
the patient with CaCl2. Again, after centrifugation, the
supernatant was discarded, and the cells were incubated
for 8 hours in the same medium to which 35S-methionine
50 lCi/mL had been added with a cocktail of protease in-
hibitors (Complete, EDTA-free) (Roche P8340). At the
end, the medium was centrifuged and the supernatant
containing the secreted peptides was kept for further pro-
cessing. Up to three 8-hour incubations could be achieved
with the same cells. When this was done, the HPLC pro-
files were qualitatively comparable.
HPLC analysis
Circulating PTH molecular forms from all sera and
from parathyroid cell incubations were extracted with
Waters Sep-Pak Plus C-18 cartridges, as described by
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Bennett et al [14]. One C-18 cartridge was used for each
3 mL of serum or medium. Samples were eluted from the
cartridge with 3 mL of 800 mL/L acetonitrile in 1 g/L tri-
fluoroacetic acid. Acetonitrile was evaporated from the
eluate with nitrogen, and the residual volume was freeze-
dried, then reconstituted in 2 mL of 1 g/L trifluroacetic
acid for HPLC analysis. Each 2 mL sample was loaded on
a Waters C18 lBondapak analytic column [300 × 3.9 mm
(inner diameter) ] and eluted with a noncontinuous lin-
ear gradient of acetonitrile in 1 g/L trifluoroacetic acid.
The gradient ranged from 15% to 23% in 25 minutes,
23% to 30% in 5 minutes, and 30% to 33% in 30 minutes.
The gradient was delivered at 1.5 mL/min with a Hitachi
Model L-6200 solvent delivery system. The 1.5 mL frac-
tions were evaporated, freeze-dried, and reconstituted to
1 mL with 7 g/L BSA in water; adequate volumes were
then measured in the various PTH assays. Controls exper-
iments were performed with hPTH (1-84) added to hy-
poparathyroid serum and with internally labeled hPTH
(1-84) added to a parathyroid cells incubation experiment
where 35S-methionine was omitted to insure that PTH
degradation did not occur during the various procedures.
After HPLC separation, a single peak of radioactivity
coeluting with hPTH (1-84) was seen and single peak of
immunoreactivity coeluting with hPTH (1-84) was de-
tected by the two PTH assays. Immunoreactive PTH re-
covery with the two PTH ELISAs through all of these
procedures was calculated by comparing original serum
or medium PTH value with the sum of PTH immunore-
activity across all HPLC fractions. For the hPTH (79-84)
assay, this was accomplished by comparing the amount
of immunoreactivity recovered by this assay with that of
the two other PTH assays.
Radioactive protein sequencing
Localization of the metabolically labeled residues was
determined by automated amino-terminal Edman degra-
dation, using Applied Biosystems sequenator (Model
Procise 494 cLC) (Foster City, CA, USA) operated ac-
cording to the manufacturer’s protocol. The only modi-
fication was the addition of narrow-bore tubing linking
the outlet of valve 39 to a programmable fraction collec-
tor. In the sequencing program, all steps involving trans-
fer to the conversion flask as well as functioning of the
conversion flask were eliminated or disabled. Transfer of
the butyl chloride (S3) extract was done directly from
the reaction cartridge to the fraction collector with func-
tions 119 and 122 each activated for a 45-second dura-
tion. Finally, prior to initiating sequencing, two complete
degradation cycles, where all additions of phenylisothio-
cyanate (PITC, R1) were omitted to condition the sam-
ple, were programmed, followed by a further cycle with
no trifluoroacetic acid addition, permitting double cou-
pling of PITC to the amino terminus in the first cycle.
The HPLC-purified and vacuum-dried sample was redis-
solved in 50 lL of water containing 1 lL of an apomyo-
globin solution (75 pmol/lL). The reconstituted sample
was then serially added (7 lL at a time) on the 6 mm glass
fiber filter on which 7.5 lL of standard Biobrene solution
had previously been added. Radioactivity at each cycle
was measured after mixing each S3 extract with 3.0 mL of
scintillation liquid cocktail (UniverSol, ICN Biomedicals,
Irvine, CA, USA) for 10 minutes’ duration in Beckman
Counter Model LS-8100.
Results are means ± SD. Planimetric evaluation of
the various HPLC profiles was accomplished with Ori-
gin 7.5 software (Origin Lab Corporation, MA, USA).
All HPLC profiles are corrected to 100% recovery and
to the patient basal PTH value expressed in pmol/L.
RESULTS
Figure 1 illustrates the immunoreactive characteristics
of the three PTH assays used in this study. The Human
Bioactive PTH ELISA Kit reacted only with hPTH (1-84)
and not with hPTH (7-84). Its revealing antibody could
be saturated with hPTH (1-34) but not with hPTH (13-
34) or hPTH (18-48). The Human PTH ELISA reacted
equally well with hPTH (1-84), hPTH (7-84), half as well
with [tyr34] hPTH (19-84) and not at all with other C-PTH
fragments, including [tyr34] hPTH (24-84). Its revealing
antibody could be completely saturated with hPTH (1-
34), about 80% with hPTH (13-34) but only 50% with
hPTH (18-48). The hPTH (79-84) RIA reacted slightly
better with hPTH (39-84) than with hPTH (1-84), hPTH
(7-84), or hPTH (53-84), the latter three being similarly
reactive. hPTH (53-83) was only about half as reactive as
hPTH (53-84) while hPTH (64-84) was even less reactive.
The biochemical and demographic characteristics of
the six patients investigated in this study are depicted on
Table 1. Patients with primary hyperparathyroidism had
more severe hypercalcemia and were hypophosphatemic.
Their AP levels varied from the upper normal limit to
frankly elevated concentrations while their PTH levels
were moderately elevated. Patients with secondary hy-
perparathyroidism had normal or slightly elevated cal-
cium levels while being hyperphosphatemic. Their AP
levels were higher than those of patients with primary
hyperparathyroidism and their PTH levels were frankly
elevated.
Figure 2 illustrates the HPLC profiles of circulating
and parathyroid cell-secreted PTH in a patient with pri-
mary (left) and secondary (right) hyperparathyroidism.
Three regions of interest were identified by the two
PTH ELISAs. The first, region 38 to 42, corresponded to
the elution position of hPTH (1-84) and was recognized
equally well by both PTH assays. The second, region 32
to 35, corresponded to an amino-terminal form of PTH
(N-PTH) which reacted less in the hPTH (12-23) assay
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Fig. 1. Immunoreactivity of the three parathyroid hormone (PTH) assays defined with the use of various human PTH calibrators and through
saturation analysis of the revealing antibody. (•) hPTH (1-84); (◦) hPTH (7-84); () hPTH (39-84); () hPTH (53-84); () hPTH (53-83); () hPTH
(64-84); () [tyr34] hPTH (19-84); (∗) [tyr34] hPTH (24-84). AU is arbitrary units.
in most HPLC profiles. Finally, the third region, region
21 to 28, corresponded to non-(1-84) PTH fragments and
reacted better in the hPTH (12-23) assay. This region was
arbitrarily divided into two regions, 3 (21 to 25) and 4 (26
to 28), for sequence analysis because region 3 had signifi-
cant hPTH (1-4) immunoreactivity while region 4 almost
none.
Table 2 summarizes the planimetric evaluation of
HPLC profiles performed on serum or parathyroid
cells supernatant. The percent of immunoreactivity
1002 D’Amour et al: Structure of non-(1-84) PTH fragments
Table 1. Characteristics of patients with primary hyperparathyroidism (PHP) and secondary hyperparathyroidism (SHP)
Biochemical measurements
Ca++ Cat PO4 Creatinine Alkaline PTH (1-4) PTH (12-23)
(1.19-1.34 (2.11-2.56 (0.77-1.4 (38-115 phosphatase (0.5-4.1 (1.5-7.0
Groups Number Gender mmol/L) mmol/L) mmol/L) lmol/L) (16-101 U/L) pmol/L) pmol/L)
PHP 1 F 1.88 2.88 0.47 56 172 24.4 42.5
2 F 1.7 3.19 0.67 73 104 17.6 18.8
3 M 1.84 3.02 0.57 91 116 24.2 33.5
Mean ± SD 1.81 3.03 0.57 73 130.7 22.1 31.6
0.09 0.16 0.10 18 36.30 3.9 12
SHP 1 M 1.35 2.32 1.55 654 346 117.8 176.6
2 M 1.21 2.22 1.73 781 163 102.2 114.5
3 M 1.3 2.41 2.14 573 129 100.4 166.6
Mean ± SD 1.29 2.32 1.81 669 212.7 106.8 152.6
0.07 0.10 0.30 105 116.7 9.6 33.3
corresponding to hPTH (1-84), N-PTH, and non-(1-84)
PTH regions are given as well as the% immunoreac-
tivity recovery with the two PTH assays in each HPLC
profile. The last was better than 80% for both PTH as-
says and in all profiles, one excepted at 71.9%. With the
hPTH (12-23) assay, there was a relatively good concor-
dance between the % of each HPLC region in serum
and parathyroid cells supernatant in both populations,
with the exception of N-PTH which was higher in the
parathyroid cells supernatant of patients with secondary
hyperparathyroidism than it was in serum. Furthermore,
the percentage of non-(1-84) PTH fragments was simi-
lar in serum and parathyroid cells supernatant in both
populations. With the PTH (1-4) assay, the amount of
N-PTH varied greatly among patients with primary hy-
perparathyroidism, from 3.3% to 45.5% in serum and
from 4.5% to 38.5% in parathyroid cells supernatant,
affecting other region results. This problem still existed
but to a lesser extend in patients with secondary hyper-
parathyroidism.
The 35S-methionine counts corresponding to HPLC re-
gions 1, 2, 3, and 4 (Fig. 2) were submitted to sequence
analysis. The results for one patient with primary hyper-
parathyroidism and one with secondary hyperparathy-
ropidism are illustrated in Figure 3. These data are also
summarized for all patients in Table 3. Peak 1, corre-
sponding to the elution position of hPTH (1-84), disclosed
35S-methionine residues at cycles 8 and 18, corresponding
to a single peptide starting at position 1 in all cases. Peak
2 gave similar results in all cases with a dominant peptide
starting at position 1, but also weaker signals at positions
5 and 15 in two cases and 2 and 12 in two other cases,
corresponding to peptides starting at positions 4 and 7,
respectively. Peak 3 gave signals at positions 8 and 18, 2
and 12, as well as four corresponding to peptides starting
at positions 1, 7, and 15. Positions 8 and 18 were the most
important quantitatively in four cases while 2 and 12 in
two cases. Peak 4 gave signals corresponding to peptides
starting at positions 1, 7, 8, 10, and 15. The most impor-
tant signal corresponded to a peptide starting at position
7 in all cases.
Figure 4 summarizes our effort to study the carboxyl-
terminal structure of these peaks, with a RIA that reacted
better with hPTH (53-84) than with hPTH (53-83), in a pa-
tient with primary hyperparathyroidism as well as in a pa-
tient with secondary hyperparathyroidism. The amount
of PTH recovered by the hPTH (1-4) and (79-84) assays
was similar for peaks 1 and 2. For the non-(1-84) region
(regions 3 and 4), the amount of immunoreactivity recov-
ered by the hPTH (79-84) assay was only 61.3% (primary
hyperparathyroidism type 2) and 83.6% (secondary hy-
perparathyroidism type 2) of the amount recovered by
the hPTH (13-23) assay.
DISCUSSION
This study was planned to elucidate the N-sequence of
non-(1-84) PTH fragments. The importance of these frag-
ments in PTH physiology has been evaluated indirectly
through the use of hPTH (7-84), a synthetic surrogate for
these fragments (8-11). Recent data suggest that these
fragments start prior to position 19 of the PTH structure
[7]. We decided to sequence internally labeled non-(1-
84) PTH fragments because this has been demonstrated
to be the most sensitive method in the past [15–17]. The
alternative, that is, sequencing purified nonradioactive
non-(1-84) PTH fragments, would have required liters of
serum from patients with very high PTH levels and liters
of medium from parathyroid cell incubations.
We initially worked with small amounts of parathy-
roid tissue (less than 500 mg) and soon discovered that
the amount of internally labeled secretion products was
too small to work with efficiently. This is why we started
to identify patients with primary or secondary hyper-
parathyroidism who had larger tumors to enroll them
in the protocol. The more severe biochemical status of
these patients reflected the greater amount of parathy-
roid tissue.
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Fig. 2. High-performance liquid chromatography (HPLC) profiles of circulating and secreted parathyroid hormone (PTH) in a patient with primary
(left) and a patient with secondary (right) hyperparathyroidism. Immunoreactivity (top and bottom graphs) was analyzed with PTH assays having
(1-4) (.....) and (12-23) (-----) epitopes. The middle graph, in each case, represents 35S-methionine counts corresponding to immunoreactivity in the
bottom graphs. Regions 1, 2, 3, and 4 corresponding to hPTH (1-84), amino-terminal PTH and non-(1-84) PTH fragments (3 and 4) were submitted
to sequence analysis (see Fig. 3).
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Table 2. Planimetric evaluation of serum and parathyroid cell medium high-performance liquid chromatography (HPLC) profiles
HPLC profile (% of total) HPLC profile (% of total)PTH (1-4) PTH (12-23)
Milieu Groups pmol/L (1-84) N-PTH Non-(1-84) Recovery pmol/L (1-84) N-PTH Non-(1-84) Recovery
PHP 1 24.4 84.5 3.3 12.2 100.9 42.5 62.8 9.1 28.2 82.1
PHP 2 17.6 62.4 25.0 12.7 85.1 18.8 71.9 4.7 23.4 71.9
PHP 3 24.2 49.4 45.4 5.2 81.6 33.5 45.1 11.3 43.6 81.1
Serum Mean ± SD 22.1 65.4 24.6 10.0 89.2 31.6 59.0 8.4 31.7 78.4
3.8 17.7 21.1 4.2 10.3 12 13.6 3.4 10.5 5.6
SHP 1 117.8 84.4 9.0 6.6 85.2 176.6 71.0 0.9 28.1 112.9
SHP 2 102.2 87.7 6.5 5.8 90.3 114.5 69.7 4.7 25.6 95.4
SHP 3 100.4 84.3 5.9 9.8 94.1 166.6 67.2 0.0 32.8 117.1
Mean ± SD 106.8 85.5 7.1 7.4 89.9 152.6 69.3 1.9 28.8 108.5
9.6 1.95 1.6 2.11 4.5 33.3 1.9 2.5 3.7 11.5
Supernatant PHP 1 2288 91.0 4.5 4.6 99 3078 75.0 5.1 20.0 99
PHP 2 3413 81.9 13.4 4.7 103 3667 72.9 7.7 19.4 99
PHP 3 880 59.5 38.5 2.0 101.6 1215 41.2 9.7 49.1 86.9
Mean ± SD 2194 77.5 18.8 3.8 100.9 2653 63.0 7.5 29.5 94.7
1269 16.2 17.6 1.5 2 1280 18.9 2.3 17 6.7
SHP 1 14487 71.2 20.3 8.5 113.1 22109 53.6 19.4 27.0 112.3
SHP 2 9330 81.4 10.1 8.5 98.5 12600 63.9 8.1 28.0 97.6
SHP 3 380 86.5 9.9 3.6 100.6 408 76.6 4.5 18.9 97.8
Mean± SD 8066 79.7 13.4 6.9 104.1 11706 64.7 10.7 24.6 102.6
7138 7.8 5.9 2.8 7.9 10878 11.5 7.8 5 8.4
Results are means ± SD. Recovery of immunoreactivity in all tubes of the HPLC profile compared to the amount loaded.
The PTH assays used for these studies corresponded
to a second generation and a third generation PTH as-
say. Based on our results and those obtained by another
study [12], the Human Bioactive PTH ELISA has a (1-4)
epitope its revealing antibody being completely saturable
with hPTH (1-34), about 50% with hPTH (2-34), 4% with
hPTH (3-34) and less than 0.1% with hPTH (4-34) [12].
The Human PTH ELISA probably has several epitopes
in the region (12-23), about 50% of them being proxi-
mal to position 18 while 50% distal to position 18. The
ending position 23 is based on non reactivity of [tyr34]
hPTH (24-84) in the assay while position 12 on the fact
that even if hPTH (13-34) was used to immunoaffinity
purify the antibody it could not completely saturate the
antibody. We also developed a RIA with an imunoaffinity
purified (79-84) antibody and 125I [tyr53] hPTH (53-84) as
tracer in which hPTH (53-84) reacted better than hPTH
(53-84) suggesting an influence of the last amino acid.
The fact that hPTH (69-84) was even less reactive than
hPTH (53-83) also suggest that the antibody may be sen-
sitive to some tertiary structure element present in hPTH
(53-83) but at least partially absent in hPTH (69-84). This
assay was mainly used to access the C-terminal structure
of non-(1-84) PTH fragments. Although, it does not con-
stitute the perfect tool, it remains the only one available
to date to address this question.
The HPLC profiles of circulating and secreted PTH
were relatively similar in all patients, with three main
regions of immunoreactivity corresponding to hPTH (1-
84) (region 1), N-PTH (region 2) and non-(1-84) PTH
(regions 3 and 4). The non-(1-84) PTH region was di-
vided into two different regions because hPTH (1-4) im-
munoreactivity was usually present in region 3 but absent
in region 4. Region 1 reacted equally in all three PTH as-
says and contained a single peptide starting at position
1. The elution position of this peptide was identical to
the one of standard hPTH (1-84), indicating similar hy-
drophobic properties. Region 2 reacted usually better in
the hPTH (1-4) and (79-84) assays than in the hPTH (12-
23) assay. This is expected because N-PTH is believed
posttranslationally modified in region (15-20) [7]. Since
the hPTH (12-23) assays has a fair amount of epitopes
in that region, one would expect decreased immunoreac-
tivity, which is not complete because epitopes proximal
to position 15 and distal to position 20 are also present.
The sequence of this peak revealed a major peptide start-
ing at position 1 in all six cases, but also minor peptides
starting at position 4 in two cases and at position 7 in
two other cases. The last could contribute to some of the
immunoreactivity detected by the hPTH (12-23) assay in
these patients. Slightly more immunoreactivity was usu-
ally detected by hPTH (12-23) and hPTH (79-84) assays
than by the hPTH (1-4) assay in region 3. Despite this,
the major peptide in that region, the one with the most
important 35S-methionine signal, was a peptide starting
at position 1 in 4 out of six cases. A peptide starting at po-
sition 7 had the most important signal in two cases, while
a minor peptide starting at position 15 was also present in
all patients. It is difficult to speculate on the structure of
the peptide starting at position 1. It is either missing part
of the C-terminal end structure or modified posttransla-
tionally differently than N-PTH (peak 2) is. There might
be a slight difference between results obtained with the
hPTH (79-84) and the hPTH (12-23) PTH assays in favor
of the latter, suggesting that all non-(1-84) PTH fragments
may not have a structure going to position 84. More data
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Fig. 3. Sequence analysis of internally labeled parathyroid hormone (PTH) molecular forms secreted by the parathyroid cells of a patient with
primary hyperparathyroidism (left) and of a patient with secondary hyperparathyroidism (right). Peaks 1, 2, 3 and 4 refer to immunoreactive peaks
identified in Figure 2 and corresponding to hPTH (1-84) (peak 1), N-PTH (peak 2), and non-(1-84) PTH (peaks 3 and 4).
are requested to address this point. Region 4 reacted both
with the hPTH (12-23) and (79-84) assays but little with
the hPTH (1-4) assay, as expected. Again immunoreac-
tivity with the hPTH (12-23) assay may be slightly more
important than with the hPTH (79-84) assay. Sequence
analysis revealed the presence of a major signal corre-
sponding to a peptide starting at position 7 in all cases.
A minor signal was also present for a peptide starting at
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Table 3. Summary of sequence analysis results
S V S E I Q L M MH N L G K L N S E R V
S V S E I Q L M MH N L G K L N S E R V
E I Q L M MH N L G K L N S E R V
L M MH N L G K L N S E R V
S V S E I Q L M MH N L G K L N S E R V
L M MH N L G K L N S E R V
ML N S E R V
S V S E I Q L M MH N L G K L N S E R V
L M MH N L G K L N S E R V
M MH N L G K L N S E R V
MH N L G K N S E R V
ML N S E R V
18
18
15
12
18
12
4
18
12
11
9
4
8
8
5
2
8
2
8
2
1
1
2
3
4
Sequence analysis of 35S -residues
Starting
position
... 1
1
4
7
1
7
15
1
7
8
10
15
Major signal 
(no/6)
6/6
0/6
0/6
4/6
2/6
0/6
0/6
6/6
0/6
0/6
0/6
Signal
(no/6)
6/6
6/6
2/6
2/6
6/6
6/6
6/6
6/6
6/6
2/6
3/6
6/6
H
H
H
H
H
H
H
H
H
LH
6/6
HPLC 
peaks
...
...
...
...
...
...
...
...
...
...
...
HPLC is high-performance liquid chromatography. 1, 2, 3, and 4 refer to HPLC peaks identified on HPLC profiles (Figure 2). Major signal indicates the most
important signal by quantity of radioactivity. Signal indicates in how many patients studied the signal was present.
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Fig. 4. Immunoreactivity of parathyroid hor-
mone (PTH) molecular forms secreted by
parathyroid cells and separated by high-
performance liquid chromatography (HPLC)
in three different PTH assays with (1-4) (.....),
(12-23) (-----), and (79-84) (••••) epitopes.
position 15 in all cases, and for minor peptides starting at
position 8 and 10 in two and three cases, respectively. We
are very confident of sequence analysis results for pep-
tides having two 35S-methionine signals (those starting at
positions 1, 4, 7, and 8) but less for those having a single
signal (starting positions 10 and 15). Although unlikely,
we cannot completely eliminate the presence of another
35S-methionine labeled peptide interference in the last
cases.
Overall, our results suggest that non-(1-84) PTH frag-
ments constitute a family of fragments which have an
N-structure starting at positions 4, 7, 8, 10, and 15, the
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peptide starting at position 7 being the major fragment.
We cannot be specific as to how exactly they are produced.
It could be both by specific cleavage at given positions or
progressive cleavage from the earlier to the latest posi-
tion as seen during the peripheral metabolism of various
125I-PTH preparations [4, 15].
The structure of non-(1-84) PTH fragments, as defined
here, points to a likely interaction with the C-PTH recep-
tor. This is based on the interaction of hPTH (7-84) and
[tyr34] hPTH (19-84) with the C-PTH receptor in various
cell lines [8, 9, 18, 19]. It is more than likely that the bio-
logical data already obtained with these peptides (8-11)
are applicable to the PTH peptides described here. This,
in turn, justifies further studies to elucidate the role of
these fragments in PTH biology.
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